m 4	٨			TEC	: כו		1710			УСЦУ			ALC:					
FURM	Washington, D.C. 20549														OMB	APPRO	VAL	
Section 16. Form 4 or Form 5 obligations may continue. See														HIP OMB Number: 323 Estimated average burden hours per response:			3235-0287 1 0.5	
1. Name and Address of Reporting Person* Bausch Christoph Lawrence (Last) (First) (Middle)				SAB Biotherapeutics, Inc. [SABS] 3. Date of Earliest Transaction (Month/Day/Year)									(Check all applicable) 10% Director 10% X Officer (give title below) Other below				10% Ov Other (s below)	vner
2100 E 54TH STREET NORTH				10/22/2021									Chief Science Officer					
(Street) SIOUX FALLS SD 57104 (City) (State) (Zip)				10/26/2021 Line) X Form fil Form fil									led by One Reporting Person led by More than One Reporting					
	Та	ble I - Nor	1-Deriv	ative	e Se	curities	s Ac	quired, I	Dis	oosed o	of, or Be	neficia	ally	Owned				
Table II - E				2. Transaction Date (Month/Day/Year)			if any		Code (Instr.		4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4			and 5) Securities Beneficia Owned Fe		Form: (D) or	n: Direct I or Indirect I nstr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
								uired, Di	spo		, or Beneficia		ly O	Transaction(s) (Instr. 3 and 4)				
2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Da	ate, 4. Co	4. Transactio Code (Ins		5. Number of Derivative		6. Date Exercisal Expiration Date		ble and 7. Title and Amo of Securities r) Underlying		d Amour ies g Security	unt 8. Price of Derivative Security		9. Number of derivative Securities Beneficially Owned Following Reported		Form: Direct (D) or Indirect	Beneficial Ownership (Instr. 4)
			Co	de V	,	(A)	(D)	Date Exercisable	e E D	xpiration ate	Title	or Numbe	r		Transaction(s) (Instr. 4)			
\$0.5	10/22/2021		ŀ			104,689		(1)(2)	0	3/12/2027	Common Stock	104,6	89	(1)(2)	104,6	89	D	
\$0.5	10/22/2021		I			81,425		(1)(2)	0	3/12/2027	Common Stock	81,42	25	(1)(2)	81,42	25	D	
(3)(4)	10/22/2021		I			108,086		(3)(4)		(3)(4)	Common Stock	108,0	86	(3)(4)	108,0	86	D	
	FORM this box if no lc n 16. Form 4 or ions may contir ions may contir ion 1(b). f(F) f(F) f(F) f(F) f(F) f(F) f(F) f(F)	FORM 4 this box if no longer subject to n 16. Form 4 or Form 5 ions may continue. See ion 1(b). nd Address of Reporting Person* a Christoph Lawrence (First) 64TH STREET NORTH FALLS SD (State) Ta Security (Instr. 3)	FORM 4 UNITED this box if no longer subject to n 16. Form 4 or Form 5 ions may continue. See tion 1(b). STAT address of Reporting Person* a Christoph Lawrence (Middle) (First) (Middle) 64TH STREET NORTH STAT FALLS SD 57104 (State) (Zip) Table 1 - Nor Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date (Month/Day/Year) \$0.5 10/22/2021 Image: Colspan="2">Image: Colspan="2" \$0.5 10/22/2	FORM 4 UNITED STATE this box if no longer subject to n 16. Form 4 or Form 5 ions may continue. See trion 1(b). STATEMEI ind Address of Reporting Person* File ind Address of Reporting Person* (Middle) ind Address of Reporting Person* (Zip) ind Address of Reporting Person* (Zip) ind Correston Date 3. Deemod Date or Exercise Price of Perivative Security 3. Deemod Date ind Addeemod Person* (Rotth/Dat//Year)	FORM 4 UNITED STATES this box if no longer subject to 10. Form 4 or Form 5 ions may continue. See thin 1(b). STATEMENT (Instrume) Ind Address of Reporting Person* 2.15 Ind Address of Reporting Person* 3.0 Ind Address of Reporting Person* 2.15 Ind Address of Reporting Person* 3.0 Ind Address of Reporting Person* 2.15 Ind Address of Reporting Person* 2.15 Ind Address of Reporting Person* 3.0 Ind Address of Reporting Person* 3.0 Ind Address of Reporting Person* 3.0 Ind	FORM 4 UNITED STATES S this box if no longer subject to 10.5 rorm 4 or Form 5 ions may continue. See tion 1(b). STATEMENT OF Filed pursuant or Sector 5 ions may continue. See tion 1(b). Filed pursuant or Sector 5 ion 2 ion	FORM 4 UNITED STATES SECUR STATEMENT OF CHAIN Into longer subject to no section or benefiting or sectin or benefiting or sectin or section or benefi	FORM 4 UNITED STATES SECURTING STATEMENT OF CHANGING STATEMENT OF CHANGING State of Porting Person* Christoph Lawrence 2. Issuer Name and Tic SAB Biotherape (First) (Middle) State of Earliest Trans 0.022/2021 Gate (Table 1 - Non-Derivative Securities Acquired (Nonth/Day/Year) Security (Instr. 3) 2. Transaction Or Exerction Date, if any (Month/Day/Year) 2. Transaction Date, if any (Month/Day/Year) 2. Transaction Date, if any (Month/Day/Year) 2. Transaction Or Exerction Securities Acquired (A) or Derivative Securities Acquired (A) or Operivative Securities Acquired (A) or Operivative Securities Securitie	FORM 4 UNITED STATES SECURITIES AND Washington, D.C. STATEMENT OF CHANGES IN B Statement of Address of Reporting Person* Address of Reporting Person* 2. Issuer Name and Ticker or Tradit SAB Biotherapeutics, In Christoph Lawrence (First) (Middle) (First) (Middle) (First) (Middle) (State) (Zip) Converting Address of Reporting Person* (First) (Middle) (State) (Zip) Converting Address of Reporting Person* (State) (Zip) Table 1 - Non-Derivative Securities Acquired, Di (Month/Day/Vear) PALLS SD 57104 (State) (Zip) Cather I - Non-Derivative Securities Acquired, Di (Bonth/Day/Vear) Patter Roman A. Deemed (Month/Day/Vear) A. Deemed (Repute Address, Catherapeutics, Di (Code (Instr. 3) A. Deemed (Repute Address, Catherapeutics, Catherapeu	FORM 4 UNITED STATES SECURITIES AND E Washington, D.C. 2054 STATEMENT OF CHANGES IN JECK IS form a or form 5 itom any continue. See this box if no longer subject to itom 100. Teled pursuant to Section 16(a) of the Securitiz or Section 30(f) of the Investment Con- or Section 30(f) of the Investment Con- state of Trainsaction (First) (Middle) christoph Lawrence (First) (Middle) 2. Issuer Name and Ticker or Trading Si SAB Biotherapeutics, Inc. [3. Date of Earliest Transaction (Month/D 10/22/2021 FALLS SD 57104 (State) (Zip) 3. Date of Carliest Transaction (Month/D 10/26/2021 Earliest Transaction (Month/Day/Year) PALLS SD 57104 (State) (Zip) 2. Transaction Date of Carliest Transaction (Month/Day/Year) 3. Transaction Date of Carliest Carliest Transaction (Month/Day/Year) 3. Transaction Date of Carliest C	FORM 4 UNITED STATES SECURITES AND EXCHA Washington, D.C. 20549 Its box if no longer subject to nate, form 4 or form 5 bion 100. STATEMENT OF CHANGES IN BENEFICI Field pursuant to Section 16(a) of the Investment Company Adv the Investment Company Adv Section 30(b) of the Investment Company Adv Address of Reporting Person* State dursuant to Section 16(a) of the Investment Company Adv Section 30(b) of the Investment Company Adv Address of Reporting Person* State of Earliest Transaction (Month/Day/Year) 10/22/2021 (First) (Middle) 3. Date of Earliest Transaction (Month/Day/Year) 10/22/2021 3. Date of Carliest Transaction (Month/Day/Year) 10/22/2021 3. Tarsaction Code (Instr. Month/Day/Year) 3. Date Securities Acquired, Disposed of (Instr. Month/Day/Year) 4. Securities Code (Instr. Month/Day/Year) 4. Securities Code (Instr. Month/Day/Year) 5. Number of Code (Instr. Month/Day/Year) 5. Number of Code (Instr. Month/Day/Year) 5. Number of Code (Instr. Month/Day/Year) 5. Number of Code (Instr. Month/Day/Year) 5. Suste Code Code (Instr. Month/Day/Year) 5.	FORM 4 UNITED STATES SECURITES AND EXCHANGE C Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OV Disposed of 000 section 30(h) of the Securities Exchange Act of 190 or Section 30(h) of the Investment Company Act of 190 or Section 30(h) of the Investment Company Act of 190 or Section 30(h) of the Investment Company Act of 190 SAB Biotherapeutics, Inc. [SABS] and Address of Reporting Person* LChristoph Lawrence (First) (Middle) SATH STREET NORTH 2. Issuer Name and Ticker or Trading Symbol SAB Biotherapeutics, Inc. [SABS] Att STREET NORTH (State) (Zip) 3. Date of Earliest Transaction (Month/Day/Year) 10/26/2021 3. Date of Carliest Transaction (Month/Day/Year) 10/26/2021 EALLS SD 57104 (State) (Zip) 2. Transaction Date (Month/Day/Year) 3. Transaction (Month/Day/Year) 4. Toenend Execurities Acquired, Disposed of, or Ben (Socurity (Instr. 3) Eacl I - Non-Derivative Securities Acquired, Disposed of, or Ben (c.g., puts, calls, warrants, orbitrors, convertiles executive (G.g., puts, calls, warrants, orbitrors, convertiles executive (G.g., puts, calls, warrants, orbitrors, convertiles executive (Instr. 3) 4. Securities Acquired, Disposed of, or Ben (Code v (a) (b) Eacling and Transaction (bonth/Day/Year) 1. Showher of Securities Code instruction Date, (G.g., puts, calls, warrants, orbitrors, convertiles acquired (Dinth/Day/Year) 1. Showher of Securities Code instruction Date, (G.g., at and 5) 5. Socurities Code instruction Date, (G.g., at and 5) 1. Socurities (C.g., puts, calls, warrants, orbitrors, convertiles Code (G.g., puts, calls, warrants, orbitrors, convertins) 1. Socuriti	FORM 4 DINTED STATES SECURITIES AND EXCHANGE COMMURATION OF Constraints of the form of	FORM 4 UNITED STATES SECURITES AND EXCHANGE COMMIS Washington, D.C. 20549 TATEMENT OF CHANGES IN BENEFICIAL OWNERSH Address of no onger subject to that with our owners and not. STATEMENT OF CHANGES IN BENEFICIAL OWNERSH Below of no onger subject to that with our ownershap is not ownershap. Id Address of Reporting Person* In Christoph Lawrence 2. Issuer Name and Ticker or Trading Symbol SAB Biotherapeutics, Inc. [SABS] 5. Ref (Christoph Lawrence) (First) (Middle) 3. Date of Earliest Transaction (Month/Day/Year) 10/22/2021 S. State of Earliest Transaction (Month/Day/Year) 10/22/2021 5. Ref (Christoph Lawrence) FALLS SD 57104 3. Date of Earliest Transaction (Month/Day/Year) 10/22/2021 5. Rem (Christoph Lawrence) 5. Securities Christoph Lawrence) 5. Rem (Christoph Lawrence) 5. Rem (Christoph Lawrence) 5. Securities Christoph Lawrence) 5. Rem (Christoph Lawrence) 5. Rem (Christoph Lawrence) 5. Rem (Christoph Lawrence) 5. Rem (Christoph Lawrence) 5. Securities Christoph Lawrence) 5. S	FORM 1 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Wahington, D. C. 2049 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHUP Is form any output to see any outpu	FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Wathington, D.C. 20549 Image: State of the owner and owner of states of the owner and owner of the owner and owner owner. See o	Prome 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Disamington, D.C. 2039 Image: properting the propropertic the properting the properis the properting the properti	Prom 4 UNITED STATES SECURITES AND EXCHANGE COMMISSION Waitington, Dr. 2009 Mathematication (a form of program person) CALL S SD STATEMENT OF CHANGES IN BENEFICIAL OWNERSIDE Section 30(1) of the Investment Conceptual Act of 1331 State and the Investment Conceptual Act of 1331 Mathematication (Christoph Lawrence) 2 issue Name and Ticle of Training Symbol (Christoph Lawrence) 2 issue Name and Ticle of Training Symbol (Christoph Lawrence) 5 issue Name and Ticle of Training Symbol (Christoph Lawrence) 5 issue Name and Ticle of Training Symbol (Christoph Lawrence) 5 issue Name and Ticle of Training Symbol (Christoph Lawrence) 5 issue Name and Ticle of Training Symbol (Christoph Lawrence) 5 issue Name and Ticle of Training Symbol (Christoph Lawrence) 5 intervidual of 3000/Group Filling (Chrict App (State) (First) (Middle) 2 issue Name and Ticle of Training Christoph (Christ State) 5 intervidual of 3000/Group Filling (Chrict App (Dorin)Dayrent) 5 intervidual App (Dorin)Dayrent)

Explanation of Responses:

1. Pursuant to the Agreement and Plan of Merger, dated June 21, 2021 and as amended August 12, 2021 (the "Business Combination Agreement"), by and among Big Cypress Acquisition Corp. ("BCYP"), Big Cypress Merger Sub Inc., and SAB Biotherapeutics, Inc. ("Old SAB Biotherapeutics"), each security to purchase shares of Old SAB Biotherapeutics common stock issued and outstanding immediately prior to the effective time of the transactions contemplated by the Business Combination Agreement was automatically converted into a security to purchase a number of shares of the Issuer's common stock based on a conversion rate of \$10.10. Upon consummation of the business combination, BCYP changed its name to "SAB Biotherapeutics, Inc." ("New SAB Biotherapeutics").

2. The option is fully vested.

3. Pursuant to the earnout provisions in the Business Combination Agreement, the reporting person is entitled to receive shares of New SAB Biotherapeutics common stock if, from the closing of the transaction until the fifth anniversary thereof, the volume-weighted average price of the common stock equals or exceeds certain thresholds (the "Earnout Shares"). Subject to adjustment as provided in the Business Combination Agreement, the Earnout Shares will be released as follows: [continued in the next footnote.]

4. 25% of the Earnout Shares will be released if within the five-year period after the closing (the "Earnout Period"), the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds \$15.00 during at least 20 trading days within a 30-day trading period; 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds \$20.00 during at least 20 trading days within a 30-day trading period; 25% of the Earnout Shares will be released if within the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds \$25.00 during at least 20 trading days within a 30-day trading period; and 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds \$30.00 during at least 20 trading days within a 30-day trading period; and 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds \$30.00 during at least 20 trading days within a 30-day trading period; and 25% of the Earnout Shares will be released if within the Earnout Period, the volume weighted share price of the New SAB Biotherapeutics common stock equals or exceeds \$30.00 during at least 20 trading days within a 30-day trading period;

Remarks:

This Form 4 amendment amends the Form 4 filed by the reporting person on October 26, 2021. This amendment is being filed to correct the expiration date of the employee stock options and the expiration date of the earnout rights.

/s/ Christoph Lawrence Bausch 11/24/2021

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.